Lactiga is an emerging biotechnology company pioneering the development of first-in-class mucosal immunotherapies. Our lead asset, LCTG-001, is a secretory IgA (sIgA) nasal spray therapy sourced from human milk, designed to restore mucosal immunity in patients with immunodeficiencies such as Common Variable Immune Deficiency (CVID). LCTG-001 is designed for chronic use with negligible systemic absorption, providing targeted protection at the mucosal surface. Lactiga holds multiple granted patents, FDA Rare Pediatric Disease and Orphan Drug designations, and is advancing toward Phase II clinical trials with a clear regulatory and CMC strategy. We are actively engaging investors to support the next stage of clinical development.